Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis

EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

EP: 4.Current Treatment Landscape for AL Amyloidosis

EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

Now Viewing

EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis

EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis

EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

The segment focuses on the safety of daratumumab in light chain (AL) amyloidosis. The phase 2 trial at Boston University showed minimal toxicity with intravenous administration, mainly infusion-related reactions that significantly reduced with subcutaneous use. The primary observed adverse effect is an increased risk of infections, particularly pneumonia. Lymphopenia and immunosuppression are potential but less pronounced adverse effects compared with those in multiple myeloma.

The discussion also highlights the cautious use of dexamethasone in combination therapies, which often necessitates reduction. Daratumumab is deemed safe with negligible neurotoxicity, in contrast to the potential neuropathy risks of other chemotherapeutic agents. The importance of supportive care for patients with multi-organ involvement is emphasized, underlining the need for an engaged medical team, including nephrologists and cardiologists, to address potential complications during therapy.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.